Our model yielded significantly improved performance over serum AFP testing for early-stage HCC versus non-HCC controls, and of the most significant clinical importance, early-stage HCC versus high-risk patients with non-malignant liver disease including LC and HBV infection. This evidence concerns the gene AFP and laryngotracheoesophageal cleft.